MEOI and HRQoL in CLL patients treated with BTKis

Inclusion Criteria

• - ≥18 years old
• - Physician-confirmed diagnosis of CLL or small lymphocytic lymphoma (SLL)
• - BTKi naïve patients who initiate acalabrutinib or ibrutinib treatment alone or in combination with an anti-CD20 mAb within 7 days (before or after) study enrollment*. Both treatment naïve and relapsed/refractory CLL patients will be included.
• - Provides informed consent
• - Adequate English reading skills
• - Able to access and use a computer, tablet, or smartphone to complete PROs